Based on the regulatory role of the mTOR pathways, mTORC1 inhibitors support the possibility of treating TSC patients based on the physiological pathogenesis, including renal angiomyolipoma, giant cell subependymal astrocytoma, and lymphatic vessel leiomyomatosis (25). The gene discussed is MTOR; the disease is subependymal giant cell astrocytoma.